The U.S. Food and Drug Administration (FDA) has tentatively authorized a advertising utility from pharmaceutical producer Sandoz for a generic model of the oral sort 2 diabetes treatment Farxiga (generic title dapagliflozin). Tentative approval signifies that the applying met approval standards however patent points must be resolved earlier than full approval is granted.
Farxiga is a member of a category of medication referred to as SGLT2 inhibitors. SGLT2, or sodium-glucose cotransporter-2, is a protein that helps the kidneys reabsorb glucose from filtered blood. SGLT2 inhibitors forestall the physique from reabsorbing this glucose, permitting it to as a substitute be handed out within the urine.
To get cutting-edge diabetes information, methods for blood glucose administration, diet ideas, wholesome recipes, and extra delivered straight to your inbox, join our free e-newsletter!
The FDA earlier this month declined Farxiga to be used as a remedy in sort 1 diabetes. The drugs was granted approval as an adjunct remedy for sure adults with sort 1 diabetes by the European Commission earlier this 12 months.
Want to study extra about SGLT2 inhbitors? Read “Diabetes Medicine: SGLT2 Inhbitors.”
Senior Digital Editor for DiabetesSelfManagement.com, Fennell has 16 years’ expertise specializing in diabetes and associated well being situations. Based in New York City, she has a level from Columbia University.